IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 101-125 out of 1367.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 > >>

Public Release: 20-Jul-2015
Current Biology
Mouse model tests health risks of circadian disturbances
People who work outside of the normal 9-5 schedule or experience frequent jet lag have been found to be at an increased risk for everything from weight gain to cancer, but there are too many variables involved to conduct multi-decade, controlled studies in humans to confirm whether sleep pattern disruption is a correlation or the cause. In Current Biology, researchers present the next best thing: a model that subjects mice to human-relevant circadian rhythm disturbances.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 20-Jul-2015
Nature Medicine
Patients' own genetically altered immune cells show promise in fighting blood cancer
In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable. The results appeared in a study published online today in Nature Medicine.
National Institutes of Health, Multiple Myeloma Research Foundation, Adaptimmune

Contact: Karen Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center

Public Release: 20-Jul-2015
Nature Genetics
'Pill on a string' could help spot early signs of cancer of the gullet
A 'pill on a string' developed by researchers at the University of Cambridge could help doctors detect esophageal cancer -- cancer of the gullet -- at an early stage, helping them overcome the problem of wide variation between biopsies, suggests research published today in the journal Nature Genetics.
Medical Research Council, Cancer Research UK

Contact: Craig Brierley
craig.brierley@admin.cam.ac.uk
44-012-237-66205
University of Cambridge

Public Release: 20-Jul-2015
Nature Medicine
Study shows promise of precision medicine for most common type of lymphoma
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study appeared online July 20, 2015, in Nature Medicine.

Contact: NCI Press Officers
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute

Public Release: 20-Jul-2015
Nature Medicine
T-cell receptor therapy achieves encouraging clinical responses in multiple myeloma
Results from a clinical trial investigating a new T cell receptor therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants.
National Institutes of Health, Multiple Myeloma Research Foundation, Adaptimmune

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-301-5221
University of Pennsylvania School of Medicine

Public Release: 20-Jul-2015
Journal of Clinical Oncology
Genomic fingerprint may predict aggressive prostate cancer in African-Americans
A set of genes could help stratify African-American men in need of more aggressive treatment for prostate cancer.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 20-Jul-2015
Nature Medicine
Stanford team links gene expression, immune system with cancer survival rates
Researchers at the Stanford University School of Medicine have compiled a database that integrates gene expression patterns of 39 types of cancer from nearly 18,000 patients with data about how long those patients lived.
Doris Duke Charitable Foundation, National Institutes of Health, B&J Cardan Oncology Research Fund, Ludwig Institute for Cancer Research, US Department of Defense, Siebel Stem Cell Institute, Thomas and Stacey Siebel Foundation

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center

Public Release: 17-Jul-2015
Science Advances
Researchers discover a possible reason for drug resistance in breast tumors
Amplified levels of HER2 membrane proteins drive unrestricted cell growth in certain types of breast cancer. HER2-tailored antibody-based therapeutics aim to prevent cancer cell growth. However, two-thirds of the patients develop resistance against such therapeutics. Why, is not yet understood. Researchers now found out that HER2 dimers appeared to be absent from a small sub-population of resting SKBR3 breast cancer cells. This subpopulation may have self-renewing properties and thus may be resistant to antibody therapy.

Contact: Niels de Jonge
niels.dejonge@leibniz-inm.de
49-681-930-0313
INM -Leibniz Insitute for New Materials

Public Release: 17-Jul-2015
Laryngoscope
Physicians testified for tobacco companies against plaintiffs with cancer, Stanford study finds
Despite scientific evidence to the contrary, a small group of otolaryngologists have repeatedly testified, on behalf of the tobacco industry, that heavy smoking did not cause the cancer in cases of dying patients suing for damages, according to a study by a Stanford University School of Medicine researcher.

Contact: Tracie White
traciew@stanford.edu
650-723-7628
Stanford University Medical Center

Public Release: 17-Jul-2015
Nature Communications
Lymphomas tied to metabolic disruption
Researchers from The University of Texas Health Science Center at San Antonio found direct links between disrupted metabolism and an often fatal type of lymphoma.
National Institutes of Health, Cancer Prevention & Research Institute of Texas

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio

Public Release: 17-Jul-2015
Angewandte Chemie International Edition
Imaging glucose uptake activity inside single cells
Researchers at Columbia University have reported a new approach to visualize glucose uptake activity in single living cells by light microscopy with minimum disturbance. In a recent study published in Angewandte Chemie International Edition, Associate Professor of Chemistry Wei Min's team developed a new glucose analogue that can mimic the natural glucose, and imaged its uptake as energy source by living cancer cells, neurons and tissues at the single cell level.

Contact: Wei Min
wm2256@columbia.edu
212-851-9433
Columbia University

Public Release: 16-Jul-2015
Cell
Scientists solve breast and ovarian cancer genetic mystery
Francis Crick Institute scientists, funded by Cancer Research UK, have solved a decades-old mystery and helped to unravel the genetic cause of some breast and ovarian cancers, according to new research published in the journal Cell.
Cancer Research UK

Contact: Greg Jones
greg.jones@cancer.org.uk
020-346-98311
Cancer Research UK

Public Release: 16-Jul-2015
JAMA Oncology
Exercising 300 minutes per week better for reducing total fat in postmenopausal women
Postmenopausal women who exercised 300 minutes per week were better at reducing total fat and other adiposity measures, especially obese women, during a one-year clinical trial, a noteworthy finding because body fat has been associated with increased risk of postmenopausal breast cancer, according to an article published online by JAMA Oncology.

Contact: Bruce Conway
bruce.conway@albertahealthservices.ca
403-943-1212
The JAMA Network Journals

Public Release: 16-Jul-2015
Nature Communications
Can protein 14-3-3 sigma prevent or kill breast cancer tumors?
Every parent knows the maxim 'feed a cold, starve a fever.' In cancer, however, exactly how to feed or starve a tumor has not been easy to determine.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 16-Jul-2015
Journal of Controlled Release
Resveratrol, quercetin could provide new options for cancer therapy
Resveratrol and quercetin, two polyphenols that have been widely studied for their health properties, may soon become the basis of an important new advance in cancer treatment, primarily by improving the efficacy and potential use of an existing chemotherapeutic cancer drug. For the first time a system has been developed that could dramatically increase the levels of these compounds in the body.

Contact: Adam Alani
adam.alani@oregonstate.edu
503-346-4702
Oregon State University

Public Release: 16-Jul-2015
JAMA Oncology
Increased radiation offers no survival benefit for patients with low-risk prostate cancer
Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology.
NIH/National Cancer Institute

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine

Public Release: 16-Jul-2015
Thyroid
30-year study shows that moderate hormone suppression may be enough in thyroid cancer
A study of long-term thyroid cancer outcomes shows, among other findings, that moderate suppression of thyroid-stimulating hormone, which drives the disease, may be as beneficial as more extreme hormone suppression. Extreme TSH suppression is associated with increased side effects including osteoporosis and heart rhythm irregularities. Results are published online ahead of print in the journal Thyroid.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 16-Jul-2015
Preventive Medicine
Sitting time not associated with poorer diets in US adults
Previously identified associations between TV viewing and a less healthful diet may stem from exposure to advertisements of high calorie foods and 'distracted eating' rather than the activity of sitting itself

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 15-Jul-2015
ACS Nano
Magnetic nanoparticles could be key to effective immunotherapy
In recent years, researchers have hotly pursued immunotherapy, a promising form of treatment that relies on harnessing and training the body's own immune system to better fight cancer and infection. Now, results of a study led by Johns Hopkins investigators suggests that a device composed of a magnetic column paired with custom-made magnetic nanoparticles may hold a key to bringing immunotherapy into widespread and successful clinical use.
NIH/National Institute of Allergy and Infectious Diseases, NIH/National Institute of General Medical Sciences, NIH/National Cancer Institute, Troper Wojcicki Foundation, Virginia and D.K. Ludwig Fund for Cancer Research

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 15-Jul-2015
Cancer Epidemiology, Biomarkers & Prevention
Breast cancer survivors gain weight at a higher rate than their cancer-free peers
Breast cancer survivors with a family history of the disease, including those who carry BRCA1 and BRCA2 gene mutations, gained more weight over the course of four years than cancer-free women -- especially if they were treated with chemotherapy, according to a prospective study by Johns Hopkins Kimmel Cancer Center researchers.
Breast Cancer Research Foundation, NIH/National Cancer Institute

Contact: Valerie Mehl
mehlva@jhmi.edu
443-375-1991
Johns Hopkins Medicine

Public Release: 15-Jul-2015
13th International Conference on Malignant Lymphoma in Lugano
PET adapted treatment improves outcome of patients with stages I/II Hodgkin Lymphoma
Final results of the randomized intergroup EORTC, LYSA (Lymphoma Study Association), FIL (Fondazione Italiana Linfomi) H10 trial presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland, on 19 June 2015 show that early FDG-PET ( 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography) adapted treatment improves the outcome of early FDG-PET-positive patients with stages I/II Hodgkin lymphoma.

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 15-Jul-2015
Nature Communications
Penn Vet team shows a protein modification determines enzyme's fate
Researchers from the University of Pennsylvania School of Veterinary Medicine show that an amino acid tag has the power to greatly influence the function of an enzyme called PRPS2, which is required for human life and can become hyperactive in cancer.
National Institutes of Health, Mari Lowe Center for Comparative Oncology

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Public Release: 15-Jul-2015
Cancer Research
Compounds show potential in fighting brain and breast cancers
The University of Hawai'i Cancer Center researchers' discovery has potential to help brain and breast cancer patients.

Contact: Nana Ohkawa
nohkawa@cc.hawaii.edu
808-564-5911
University of Hawaii Cancer Center

Public Release: 15-Jul-2015
Trends in Biochemical Sciences
Defective telomeres are now being linked to dozens of diseases, including many types of cancer
Studying telomeres, the structures that protect the ends of chromosomes, has become a key issue in biology. In recent years, not only has their relation to aging been confirmed; defective telomeres seem to be linked to more and more illnesses, including many types of cancer.

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 15-Jul-2015
Analytical Chemistry
A portable 'paper machine' can diagnose disease for less than $2
In the US and other industrialized nations, testing for infectious diseases and cancer often requires expensive equipment and highly trained specialists. In countries where resources are limited, performing the same diagnostics is far more challenging. To address this disparity, scientists are developing a portable, low-cost 'paper machine' for point-of-care detection of infectious diseases, genetic conditions and cancer. Their report appears in the ACS journal Analytical Chemistry.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Showing releases 101-125 out of 1367.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 > >>

  Search News Releases

     

 

EurekAlert!